Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 18/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23925682 | 1.00 | EGLN2 (0.51) | EGLN2CYP11B1CYP11B2PIK3CDPIK3R1 | |
| SCHEMBL23944196 | 1.00 | EGLN2 (0.51) | EGLN2CYP11B1CYP11B2PIK3CDPIK3R1 | |
| SCHEMBL23925376 | 0.88 | EGLN2 (0.46) | EGLN2 | |
| SCHEMBL23944790 | 0.88 | EGLN2 (0.46) | EGLN2 | |
| SCHEMBL23943814 | 0.88 | EGLN2 (0.46) | EGLN2 | |
| SCHEMBL23925401 | 0.85 | EGLN2 (0.57) | EGLN2 | |
| SCHEMBL25616320 | 0.84 | PAX2 (0.44) | — | |
| SCHEMBL25616303 | 0.84 | PAX2 (0.44) | — | |
| SCHEMBL8912330 | 0.82 | TSHR (0.41) | EGLN2 | |
| SCHEMBL5593122 | 0.80 | PAX2 (0.37) | EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167121-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-01 | — | — | US | disclosed |
| US-20230167121-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-01 | — | — | US | disclosed |
| US-20230167121-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-01 | — | — | US | disclosed |
| EP-4136089-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | The Trustees of The University of Pennsylvania (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115397826-A | Substituted {1,2,4, } triazolo {1,5-a } pyrimidine compounds and their use for the stabilization of microtubules | 宾夕法尼亚大学理事会 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021211408-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211408-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167121-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | MAPT, TUBA4A, MAP4 | EGLN2 4728/4885CYP11B1 4554/4885CYP11B2 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.